WO2026050777 - STABLE LIQUID FORMULATIONS OF FROVATRIPTAN
National phase entry is expected:
Publication Number
WO/2026/050777
Publication Date
05.03.2026
International Application No.
PCT/US2025/044544
International Filing Date
02.09.2025
Title **
[English]
STABLE LIQUID FORMULATIONS OF FROVATRIPTAN
[French]
FORMULATIONS LIQUIDES STABLES DE FROVATRIPTAN
Applicants **
PATEL, Sandipkumar
Inventors
PATEL, Sandipkumar
Priority Data
63/689,763
01.09.2024
US
63/869,504
25.08.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
|
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2391 | |
| EPO | Filing, Examination, Granting | 10615 | |
| Japan | Filing, Examination, Granting | 2397 | |
| South Korea | Filing, Examination, Granting | 2502 | |
| USA | Filing, Examination, Granting | 5530 |
Total:
23,435
Contact Us
Abstract[English]
Liquid pharmaceutical formulations of frovatriptan, or a pharmaceutically acceptable salt thereof, intended for non-oral administration is disclosed. The formulations include frovatriptan, a liquid vehicle, and one or more optional pharmaceutically acceptable excipients, and demonstrate stability at room temperature for an extended period. The method of preparation for the liquid frovatriptan formulation as well as its therapeutic application in diseases treatable with frovatriptan are also described.[French]
L'invention concerne des formulations pharmaceutiques liquides de frovatriptan, ou un sel pharmaceutiquement acceptable de celui-ci, destinées à une administration non orale. Les formulations comprennent du frovatriptan, un véhicule liquide et un ou plusieurs excipients pharmaceutiquement acceptables facultatifs, et présentent une stabilité à température ambiante pendant une période étendue. L'invention concerne également le procédé de préparation de la formulation liquide de frovatriptan ainsi que son application thérapeutique dans des maladies pouvant être traitées avec du frovatriptan.